ASCO 2026 preview – Celcuity gets a mutant coup
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA-mutant, as well as in wild-type disease.
The month ahead: March’s upcoming events
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
Celcuity goes early with its Pfizer cast-off
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
